Click here for slides on this topic


Abbreviation for tumor necrosis factor-a, an inflammatory cytokine produced by macrophases and, to a lesser degree, by fat cells. TNF-a induces matrix-degrading enzymes necessary for vascular smooth cell migration characteristic of advanced atherosclerotic lesions. TNF-a also inhitis lipoprotein lipase, the major enzyme involved in triglyceride catabolism, and insulin signaling in skeletal muscle.
The following content matched the glossary term: TNF-alpha Expert Commentary Silvio E. Inzucchi MD on the Association Between Severe Hypoglycemia


EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "This paper adds to a growing body of literature demonstrating the higher cardiovascular risk of patients with type 2 diabetes and a history of severe hypoglycemia"

The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers


Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Jr DC. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res Clin Pract. 2011 Oct 21. [Epub ahead of print]. To determine whether intensive risk factor management reduced markers of inflammation in middle-aged and older people with type 2 diabetes who either had, or were at risk for cardiovascular disease (CVD), and whether these effects were mediated by adiposity.

Overweight Latino children/adolescents have marked endothelial dysfunction & subclinical vascular inflammation w excess body fat & insulin resistance


Caballero AE, Bousquet-Santos K, Robles-Osorio L, et al. Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care. 2008;31(3):576-582. We measured plasma markers of endothelial dysfunction, vascular inflammation, and pro-coagulation in obese Hispanic/Latino children and adolescents with normal glucose tolerance and determined their relationship to body composition and indexes of glucose and lipid metabolism.

Evidence for a potent antiinflammatory effect of rosiglitazone


Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728-2735. We have recently demonstrated a potent antiinflammatory effect of troglitazone, an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) and a partial agonist of PPAR-alpha in both the nondiabetic obese and diabetic obese subjects.

Suppression of Nuclear Factor-kappaB and Stimulation of Inhibitor kappaB by Troglitazone


Ghanim H, Garg R, Aljada A, et al. Suppression of Nuclear Factor-B and Stimulation of Inhibitor B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese. Endocrinology. 2001;86:1306-1312. To elucidate whether troglitazone exerts an antiinflammatory effect in humans, in vivo, we investigated the suppression of nuclear factor kappaB (NFkappaB) in mononuclear cells (MNC) by this drug.

Troglitazone Reduces Plasma TNF-a Levels As it Improves Insulin Sensitivity in Obese Diabetic Patients


Katsuki A, Sumida Y, Murata K, et al. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2000;2:189-191. We evaluated the effect of troglitazone (given orally 400 mg/day) on glucose intolerance and on the plasma levels of tumour necrosis factor-alpha (TNF-alpha) in 12 obese patients with type 2 diabetes for 12 weeks. Troglitazone significantly decreased fasting plasma glucose, serum C-peptide, serum insulin and HbA1c levels.

Slide Library Results

Search Results for: TNF-alpha Slides Found: 1
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI